In drug development, the right biomarker can mean the difference between success and a missed opportunity.
In this episode of SNiPs, Bracken Senior Partner David Raunig, PhD explores how imaging biomarkers—like DXA and the fracture risk score—are being used in new ways to assess efficacy in clinical trials, especially for rare and complex diseases.
David breaks down the evolving landscape of FDA qualification, highlighting a flexible path that allows sponsors to leverage novel endpoints without requiring tens of thousands of patients. From muscle mass in aging populations to trial-specific biomarker strategies, he shares valuable insight into what’s possible today—and what’s coming next.
Tune in to hear David's insights, and subscribe to Fractals on your favorite podcast platform to be the first to hear the full conversation; contact us today to learn more.